Heart 1998;79:9-10 ( January )
Editorial
Enthusiasm, reality, and cost-effectiveness analysis
| The first 150 words of the full text of this article appear below. |
The enthusiasm of researchers and clinical investigators is an admirable and perhaps necessary trait for performing good clinical research but must not obscure the interpretation of trial results. Cost-effectiveness analysis is being promoted as an objective means to measure the balance between the effectiveness of a treatment and its cost. Although cost-effectiveness analysis in medicine is in its infancy, much work has been performed to solidify its methodological underpinnings.1-3 Clinicians, nevertheless often remain suspicious of the process as they realise how difficult it may be to have reliable cost and efficacy information.
This issue contains an article by Aristides and colleagues on the cost-effectiveness of abciximab in preventing restenosis following percutaneous transluminal coronary angioplasty (PTCA).4 We agree wholeheartedly with the caveats expressed by Glasziou in his accompanying editorial5 and add some further worries in this commentary.
The key ratio in cost-effectiveness analysis has a numerator of costs
and a denominator
This article has been cited by other articles:
-
Eisenberg, M. J.
(2006). Drug-Eluting Stents: The Price Is Not Right. Circulation
114: 1745-1754
[Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
